Most Read Articles
Pearl Toh, 18 Feb 2016
Treatment with eluxadoline, a new oral medication, relieved two major symptoms of irritable bowel syndrome with diarrhoea (IBS-D) — abdominal pain and diarrhoea, according to a study based on two phase III randomized controlled trials. [N Engl J Med 2016;374:242-253]
01 Apr 2016
Amiodarone is safe and effective for early junctional ectopic tachycardia prophylaxis in paediatric patients following open heart surgery, based on a study.
Tristan Manalac, 6 days ago
Taking oral antibiotics appears to increase the risk of nephrolithiasis, according to a recent study. Moreover, the risk seems to be compounded for individuals with recent antibiotic exposure and those who were exposed at a younger age.
Roshini Claire Anthony, 20 Mar 2018

Individuals with type 2 diabetes (T2D) who initiate therapy with sodium glucose cotransporter-2 (SGLT-2) inhibitors have lower risks of all-cause death and cardiovascular (CV) outcomes, specifically myocardial infarction (MI) and stroke, compared with those who initiate other glucose-lowering therapies, according to results from the CVD-REAL* 2 study.

Do proton pump inhibitors promote development of dementia?

24 Aug 2017

Use of proton pump inhibitors (PPIs) does not appear to have any effect on cognitive function, with a recent study suggesting that the drugs do not increase the risk of dementia.

Researchers examined data on medication use and other potential risk factors from 13,864 participants in the Nurses’ Health Study II. All participants completed a self-administered computerized neuropsychological test battery.

Multivariable linear regression analysis found a modest association between duration of PPI use and scores for psychomotor speed and attention. The mean score difference for PPI use of 9 to 14 years vs nonuse was –0.06 (95 percent CI, –0.11 to 0.00; p=0.03 for trend). However, the magnitude of this score difference shrank after adjusting for the use of H2 receptor antagonists (H2RAs).

Among individuals who were not regular PPI users, duration of H2RA use was associated with poor cognitive scores, and this relationship was most pronounced for learning and working memory (mean score difference for H2RA users of 9 to 14 years vs nonusers, –0.20; –0.32 to –0.08; p<0.001 for trend).

The present data do not support the suggestion that PPI use increases dementia risk, researchers said, adding that findings for H2RAs should be interpreted with caution as the primary hypothesis was related to PPI use.

While the underlying mechanism by which PPIs might influence the development of dementia is unclear, there are pieces of evidence linking PPI use to cognitive decline. Several studies have shown that some PPIs (eg, lansoprazole and omeprazole) could cross the blood-brain barrier and directly affect the brain. The drugs are also said to be capable of interacting with brain enzymes, as well as inducing increased amyloid beta levels in an amyloid cell model and in the brains of mice. [PLoS One 2013;8:e58837; J Chromatogr A 2002;949:35-42; J Alzheimers Dis 2010;19:573-589]

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 18 Feb 2016
Treatment with eluxadoline, a new oral medication, relieved two major symptoms of irritable bowel syndrome with diarrhoea (IBS-D) — abdominal pain and diarrhoea, according to a study based on two phase III randomized controlled trials. [N Engl J Med 2016;374:242-253]
01 Apr 2016
Amiodarone is safe and effective for early junctional ectopic tachycardia prophylaxis in paediatric patients following open heart surgery, based on a study.
Tristan Manalac, 6 days ago
Taking oral antibiotics appears to increase the risk of nephrolithiasis, according to a recent study. Moreover, the risk seems to be compounded for individuals with recent antibiotic exposure and those who were exposed at a younger age.
Roshini Claire Anthony, 20 Mar 2018

Individuals with type 2 diabetes (T2D) who initiate therapy with sodium glucose cotransporter-2 (SGLT-2) inhibitors have lower risks of all-cause death and cardiovascular (CV) outcomes, specifically myocardial infarction (MI) and stroke, compared with those who initiate other glucose-lowering therapies, according to results from the CVD-REAL* 2 study.